The Immuno-Oncology Program was established in 2025 to build on MSK’s pioneering contributions in the development of immune checkpoint blockade therapy, chimeric antigen receptor (CAR-T) and other cellular therapies, and cancer vaccines. The program continues and expands the vital work to understand how cancer evades the immune system and to make immunotherapy effective for more patients and cancer types.

The program serves as a central hub for immuno-oncology research at MSK, working in close collaboration with MSK’s world-renowned basic and translational research programs, collaborative research centers, and cutting-edge core facilities. The program’s physician-scientists are uniquely positioned to bridge the gap between laboratory research and patient treatment, leveraging MSK’s extensive clinical expertise and infrastructure to study clinically relevant mechanisms.

Collaborations & Resources

MSK offers a wide array of core facilities and state-of-the-art technologies, as well as significant opportunity for collaboration. Scientists in the Immuno-Oncology Program derive particular benefit from close ties to the following:

• Human Oncology & Pathogenesis Program
• Immunology Program
• Center for Cell Engineering
• Center for Experimental Immuno-Oncology
• Center for Experimental Therapeutics
• Center for Tumor-Immune Systems Biology
• Core Facilities and Resources
• Ludwig Center for Cancer Immunotherapy
• Marie-Josée Kravis Center for Cancer Immunobiology
• Marie-Josée and Henry R. Kravis Cancer Ecosystems Project
• Olayan Center for Cancer Vaccines at MSK
• Parker Institute for Cancer Immunotherapy
• SKI Innovation Labs